Show notes
Since the results of the US election, the news has been awash with what the future might hold under a second Trump Administration, particularly within healthcare and life sciences.In today’s podcast, web editor Nicole Raleigh is joined by Jesse Mendelsohn, senior vice president of Model N’s Center of Excellence, for a conversation that explores multiple aspects of the drug pricing debate in America – speaking before President-Elect Donald Trump confirmed his nomination of Robert F Kennedy Jr as US Health and Human Services Secretary.Mendelsohn – using history as a guide – suggests there will be a layering of new laws, with, for example, a push for changes to the Inflation Reduction Act, rather than repeal of it. And he explores the potential impacts on pharma, also.



